5 / 24
Clinical Development
Fase I
Expansion
cohort
Non-BRCA
mutated
RR 50% (8/16) in
OC and BRCA mut
Dose up to 400 bid
Fong P et al. New Eng J Med 2009
RR 43% (23/50)
OC and BRCA mut
Fong P et al. J Clin Oncol 2010
RR 24% (11/46)
OC and BRCA wt
Gelmon KA, et al. Lancet Oncol 2011;12:852–61